Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31251126 | 0.89 | CASP3 (0.51) | CASP3KMT2APIN1CTSLCTSB | |
| SCHEMBL14019298 | 0.89 | POLB (0.51) | CASP3KMT2APIN1EPHX2POLB | |
| SCHEMBL31546599 | 0.89 | POLB (0.51) | CASP3KMT2APIN1EPHX2POLB | |
| SCHEMBL9269897 | 0.87 | PIN1 (0.52) | CASP3KMT2APIN1EPHX2 | |
| SCHEMBL15434562 | 0.87 | CTSL (0.50) | CASP3KMT2APIN1CTSLCTSB | |
| SCHEMBL30582698 | 0.87 | CASP3 (0.54) | CASP3KMT2APIN1CTSLCTSB | |
| SCHEMBL6038102 | 0.86 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2 | |
| SCHEMBL118209 | 0.86 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2 | |
| SCHEMBL119497 | 0.86 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2 | |
| SCHEMBL1486214 | 0.86 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003276-A1 | Methods for treating anthrax and inhibiting lethal factor | HERMES JEFFERY D | 2010-01-07 | — | — | US | disclosed |
| US-7504425-B2 | Compounds useful in the treatment of anthrax and inhibiting lethal factor | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003276-A1 | Methods for treating anthrax and inhibiting lethal factor | ANTXR2, SERPINB1, APAF1 | CASP3 516/4885KMT2A 4071/4885PIN1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.